Previous 10 | Next 10 |
Pieris Pharmaceuticals (PIRS) soars 15% premarket after Seagen (SGEN) makes a strategic equity investment in the company as part of an ongoing collaboration between them.The companies have amended their existing immuno-oncology agreement around joint development and commercial right...
Seagen will supply Pieris with TUKYSA® to evaluate the drug in combination with cinrebafusp alfa (PRS-343) in gastric cancer Pieris' co-development option for one program from existing multi-target collaboration amended to US co-promotion option with increased royalties if exercis...
BOSTON, MA / ACCESSWIRE / March 23, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced ...
BOSTON, MA / ACCESSWIRE / February 23, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today anno...
The FDA has lifted partial clinical hold on Phase 1 studies evaluating Pieris Pharmaceuticals' ([[PIRS]] +3.4%) lead candidate, PRS-343. As previously guided, the Company intends to move into a proof-of-concept study of PRS-343 in gastroesophageal cancer.The FDA instituted a partial...
BOSTON, MA / ACCESSWIRE / January 19, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, tod...
Ocugen (OCGN) +127%.The9 Limited (NCTY +62% after signing a legally binding cooperation and investment term sheet.Bionano Genomics (BNGO +44% on publishing study on Autism Risk Genes.ViewRay (VRAY +23% on preliminary Q4 results.AirNet Technology (ANTE +28%...
Pieris Pharmaceuticals, Inc. (PIRS) Q3 2020 Results Conference Call November 04, 2020 08:00 AM ET Company Participants Tom Bures - VP, Finance Steve Yoder - President and CEO Hitto Kaufmann - Chief Scientific Officer Shane Olwill - SVP and Head, Translational Science Conference Call Participa...
Pieris Pharmaceuticals (PIRS) Q3 net loss was $14.3M or EPS of$0.26, misses consensus by $0.13. This compares to a net loss of $2.6M or EPS loss of $0.05.G&A expense were $4.1M, compared to $4.8M.R&D expenses were $11.8M, compared to $13.2M.Cash, cash equivalents, and investments...
Pieris Pharmaceuticals (PIRS): Q3 GAAP EPS of -$0.26 misses by $0.13.Revenue of $2.94M (-80.6% Y/Y) misses by $8.78M.Press Release For further details see: Pieris Pharmaceuticals EPS misses by $0.13, misses on revenue
News, Short Squeeze, Breakout and More Instantly...
Pieris Pharmaceuticals Inc. Company Name:
PIRS Stock Symbol:
NASDAQ Market:
Pieris Pharmaceuticals Inc. Website:
2024-07-27 03:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 75.8% to $0.0457 on volume of 1,196,767,473 shares NVIDIA Corporation (NVDA) fell 6.8% to $114.25 on volume of 316,196,296 shares Sangamo Therapeutics Inc. (SGMO) rose 39.5% to $0.56 on volume of 261...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...